- Home
- TGHL vs ADXN Comparison
TGHL vs ADXN Comparison
Compare TGHL & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGHL | ADXN |
|---|---|---|
| Founded | 2020 | 2002 |
| Country | Singapore | Switzerland |
| Employees | 7 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 8.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | TGHL | ADXN |
|---|---|---|
| Price | $0.34 | $6.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 26.9K | 2.1K |
| Earning Date | 05-18-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $5.41 |
| 52 Week High | $3.80 | $12.05 |
Technical Indicators
Market Signals| Indicator | TGHL | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 50.86 | 46.44 |
| Support Level | $0.33 | $6.04 |
| Resistance Level | $0.40 | $7.40 |
| Average True Range (ATR) | 0.03 | 0.30 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 43.67 | 49.28 |
Price Performance
Historical ComparisonAbout TGHL The GrowHub Limited Class A Ordinary Shares
The Growhub Ltd operates at the intersection of technology and supply chain management in the food industry, focusing on enhancing product traceability and authenticity. With a commitment to innovation and sustainability, It has developed a multi-faceted approach to address industry challenges. its business currently comprises two main divisions, which are the GrowHub Platform and its product trading facilitation offering.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.